ASH 2017

0:00:50

Progress still being made in MM: highlights of ASH 2017

0:03:57

ASH 2017 President’s meeting highlights

0:01:36

ASH 2017 highlights: Cell therapy approaches in ALL

1:02:47

ASH 2017: IMWG Conference Series

0:01:15

Dr. N Lehners | ASH 2017 | Key highlights: Myeloma - pathophysiology & pre-clinical studies

0:01:05

Prof. Ross Levine | ASH 2017 | Molecular pathogenesis of AML

0:04:21

ASH 2017 update on progress with novel AML treatments at MD Anderson

0:03:08

AML highlights from ASH 2017

0:55:06

ASH 2017 Highlights on myeloma

0:02:29

Ibrutinib combination regimens for CLL from ASH 2017

0:02:18

Advancements at ASH 2017 that are directly relevant to patients

0:01:18

ASH 2017 top picks: Phase III trials, antibody-drug conjugates and CAR T-cells

0:04:06

Precision medicine, genomics and immunotherapies at ASH 2017

0:03:54

Prof. Sonali Smith | ASH 2017 | Highlights of ASH 2017 in aggressive NHL

0:04:19

ASH 2017 - Shaji Kumar Interview

0:00:41

The analysis of neurotoxicity at ASH 2017

0:05:29

MPNs update from ASH 2017

0:19:15

Medscape Perspectives | ASH 2017 Breakthroughs Clinical Trials

0:01:08

Prof. Juliusson | ASH 2017 | Molekylär karaktärisering och epidemiologi hos AML- vuxna i Sverige

0:01:34

Multiple myeloma highlights at ASH 2017

0:04:12

Major breakthroughs in AL amyloidosis treatment from ASH 2017

0:04:53

Prof. Nathan Fowler | ASH 2017 | Highlights of ASH 2017 in Follicular Lymphoma

0:05:37

Key abstracts being presented at ASH 2017

0:02:12

Prof. Eduardo Rego | ASH 2017 | Take home message to Brazil from ASH 2017